Brief: Moonlake Immunotherapeutics Topline Primary Endpoint Readout At Week 16 For Phase 3 IZAR Program Expected In H1 2026
13/11/2024 13:04
Nov 13 (Reuters) - MoonLake Immunotherapeutics MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS: TOPLINE PRIMARY ENDPOINT
READOUT AT
WEEK 16 FOR PHASE 3 IZAR PROGRAM EXPECTED IN H1 2026
Source text: ID:nGNX4DKMdp
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial